Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator

Samba O Sow, Milagritos D Tapia, Wilbur H Chen, Fadima C Haidara, Karen L Kotloff, Marcela F Pasetti, William C Blackwelder, Awa Traoré, Boubou Tamboura, Moussa Doumbia, Fatoumata Diallo, Flanon Coulibaly, Uma Onwuchekwa, Mamoudou Kodio, Sharon M Tennant, Mardi Reymann, Diana F Lam, Marc Gurwith, Michael Lock, Thomas Yonker, Jonathan Smith, Jakub K Simon, Myron M Levine, Samba O Sow, Milagritos D Tapia, Wilbur H Chen, Fadima C Haidara, Karen L Kotloff, Marcela F Pasetti, William C Blackwelder, Awa Traoré, Boubou Tamboura, Moussa Doumbia, Fatoumata Diallo, Flanon Coulibaly, Uma Onwuchekwa, Mamoudou Kodio, Sharon M Tennant, Mardi Reymann, Diana F Lam, Marc Gurwith, Michael Lock, Thomas Yonker, Jonathan Smith, Jakub K Simon, Myron M Levine

Abstract

Reactive immunization with a single-dose cholera vaccine that could rapidly (within days) protect immunologically naive individuals during virgin soil epidemics, when cholera reaches immunologically naive populations that have not experienced cholera for decades, would facilitate cholera control. One dose of attenuated Vibrio cholerae O1 classical Inaba vaccine CVD 103-HgR (Vaxchora) containing ≥2 × 108 CFU induces vibriocidal antibody seroconversion (a correlate of protection) in >90% of U.S. adults. A previous CVD 103-HgR commercial formulation required ≥2 × 109 CFU to elicit high levels of seroconversion in populations in developing countries. We compared the vibriocidal responses of Malians (individuals 18 to 45 years old) randomized to ingest a single ≥2 × 108-CFU standard dose (n = 50) or a ≥2 × 109-CFU high dose (n = 50) of PaxVax CVD 103-HgR with buffer or two doses (n = 50) of Shanchol inactivated cholera vaccine (the immunologic comparator). To maintain blinding, participants were dosed twice 2 weeks apart; CVD 103-HgR recipients ingested placebo 2 weeks before or after ingesting vaccine. Seroconversion (a ≥4-fold vibriocidal titer rise) between the baseline and 14 days after CVD 103-HgR ingestion and following the first and second doses of Shanchol were the main outcomes measured. By day 14 postvaccination, the rates of seroconversion after ingestion of a single standard dose and a high dose of CVD 103-HgR were 71.7% (33/46 participants) and 83.3% (40/48 participants), respectively. The rate of seroconversion following the first dose of Shanchol, 56.0% (28/50 participants), was significantly lower than that following the high dose of CVD 103-HgR (P = 0.003). The vibriocidal geometric mean titer (GMT) of the high dose of CVD 103-HgR exceeded the GMT of the standard dose at day 14 (214 versus 95, P = 0.045) and was ∼2-fold higher than the GMT on day 7 and day 14 following the first Shanchol dose (P > 0.05). High-dose CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess its efficacy and practicality in field situations. (This study has been registered at ClinicalTrials.gov under registration no. NCT02145377.).

Keywords: Mali; cholera vaccine; immunogenicity; live oral vaccine; reactive vaccination; single-dose vaccine.

Copyright © 2017 Sow et al.

Figures

FIG 1
FIG 1
CONSORT (Consolidated Standards of Reporting Trials) diagram.
FIG 2
FIG 2
(Left) Percentage of vaccinees in each group who seroconverted by the indicated day of follow-up; (middle) kinetics of the geometric mean titer (GMT) of the serum vibriocidal antibody by the indicated day of follow-up; (right) kinetics of the geometric mean fold rise (GMFR) of the serum vibriocidal antibody by the indicated day of follow-up.

References

    1. Swerdlow DL, Mintz ED, Rodriguez M, Tejada E, Ocampo C, Espejo L, Greene KD, Saldana W, Seminario L, Tauxe RV. 1992. Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk. Lancet 340:28–33. doi:10.1016/0140-6736(92)92432-F.
    1. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW. 2013. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med 368:599–609. doi:10.1056/NEJMoa1204927.
    1. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, Chaignat CL. 2004. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22:2444–2451. doi:10.1016/j.vaccine.2003.11.070.
    1. Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467–470.
    1. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. 1993. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol Lett 111:15–21. doi:10.1111/j.1574-6968.1993.tb06355.x.
    1. Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. 2017. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines 16:197–213. doi:10.1080/14760584.2017.1291348.
    1. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 60:4430–4432.
    1. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. 1999. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 67:6341–6345.
    1. Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. 2016. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 62:1329–1335. doi:10.1093/cid/ciw145.
    1. Mosley WH, Ahmad S, Benenson AS, Ahmed A. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 38:777–785.
    1. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151:236–242. doi:10.1093/infdis/151.2.236.
    1. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. 31 May 2017. Antibody-based correlates of protection against cholera analysis of a challenge study in a cholera-naive population. Clin Vaccine Immunol. doi:10.1128/CVI.00098-17.
    1. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, Ryan ET, Qadri F, Calderwood SB. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2:e221. doi:10.1371/journal.pntd.0000221.
    1. Mosley WH, Benenson AS, Barui R. 1968. A serological survey for cholera antibodies in rural east Pakistan. I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera. Bull World Health Organ 38:327–334.
    1. Herzog C. 2016. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. Travel Med Infect Dis 14:373–377. doi:10.1016/j.tmaid.2016.07.003.
    1. Levine MM. 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8:129. doi:10.1186/1741-7007-8-129.
    1. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Lim YL, Burr D, Wasserman SS, Kaper J, Sorenson K, Cryz S, Levine MM. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340:689–694. doi:10.1016/0140-6736(92)92231-4.
    1. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata CF, Wasserman SS, Salazar E, Kaper JB, Cryz S, Levine M. 1993. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 61:3994–3997.
    1. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttitham P, Lim YL, Losonsky G, Kaper JB, Wasserman SS, Cryz S, Echeverria P, Levine MM. 1992. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 165:1042–1048. doi:10.1093/infdis/165.6.1042.
    1. Van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, Rubin DB. 2006. Fully conditional specification in multivariate imputation. J Stat Comp Sim 76:1049–1064. doi:10.1080/10629360600810434.
    1. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai A, Wasserman SS, Losonsky GA, Kaper J, Cryz S, Levine MM. 1993. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. J Infect Dis 168:1169–1176. doi:10.1093/infdis/168.5.1169.
    1. Lagos R, Avendano A, Prado V, Horwitz I, Wasserman SS, Losonsky G, Cryz SC Jr, Kaper JB, Levine MM. 1995. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 63:707–709.
    1. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM. 1999. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J 18:624–630. doi:10.1097/00006454-199907000-00011.
    1. Mosley WH, McCormack WM, Ahmed A, Chowdhury AK, Barui RK. 1969. Report of the 1966-67 cholera vaccine field trial in rural east Pakistan. 2. Results of the serological surveys in the study population—the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ 40:187–197.
    1. Kauffman RC, Bhuiyan TR, Nakajima R, Mayo-Smith LM, Rashu R, Hoq MR, Chowdhury F, Khan AI, Rahman A, Bhaumik SK, Harris L, O'Neal JT, Trost JF, Alam NH, Jasinskas A, Dotsey E, Kelly M, Charles RC, Xu P, Kovac P, Calderwood SB, Ryan ET, Felgner PL, Qadri F, Wrammert J, Harris JB. 2016. Single-cell analysis of the plasmablast response to Vibrio cholerae demonstrates expansion of cross-reactive memory B cells. mBio 7:e02021-16. doi:10.1128/mBio.02021-16.
    1. Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, Desai SN, Singh AP, Kim IY, Kim CW, Park SN. 2015. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol versus Shanchol) in the Philippines. Vaccine 33:6360–6365. doi:10.1016/j.vaccine.2015.08.075.
    1. Wierzba TF, Kar SK, Mogasale VV, Kerketta AS, You YA, Baral P, Khuntia HK, Ali M, Kim YH, Rath SB, Bhattachan A, Sah B. 2015. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. Vaccine 33:2463–2469. doi:10.1016/j.vaccine.2015.03.073.
    1. Qadri F, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Begum YA, Bhuiyan TR, Chowdhury MI, Uddin MJ, Khan JA, Chowdhury AI, Rahman A, Siddique SA, Asaduzzaman M, Akter A, Khan A, Ae YY, Siddik AU, Saha NC, Kabir A, Riaz BK, Biswas SK, Begum F, Unicomb L, Luby SP, Cravioto A, Clemens JD. 2015. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 386:1362–1371. doi:10.1016/S0140-6736(15)61140-0.
    1. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page AL, Quilici ML, Mengel MA, Eiros JM, Serafini M, Legros D, Grais RF. 2014. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370:2111–2120. doi:10.1056/NEJMoa1312680.
    1. Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Asaduzzaman M, Akter A, Khan A, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Islam T, Chowdhury AI, Rahman A, Siddique SA, You YA, Kim DR, Siddik AU, Saha NC, Kabir A, Cravioto A, Desai SN, Singh AP, Clemens JD. 2016. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med 374:1723–1732. doi:10.1056/NEJMoa1510330.
    1. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29:8285–8292. doi:10.1016/j.vaccine.2011.08.108.
    1. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, Holmgren J, Clemens JD, Sur D. 2009. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 27:6887–6893. doi:10.1016/j.vaccine.2009.09.008.
    1. Richie E, Punjabi NH, Sidharta Y, Peetosutan K, Sukandar M, Wasserman SS, Lesmana M, Wangsasaputra F, Pandam S, Levine MM, O'Hanley P, Cryz SJ, Simanjuntak CH. 2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399–2410. doi:10.1016/S0264-410X(00)00006-2.
    1. Lagos R, Losonsky G, Abrego P, San Martin O, Prado V, Wasserman S, Levine MM. 1996. Tolerancia, immunogenicidad, excresión y transmisión de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en niños Chilenos de 24 a 59 meses. Bol Hosp Infant Mex 53:214–220.
    1. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, Losonsky GA, Alegria S, Levine MM. 1999. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 180:1709–1712. doi:10.1086/315051.
    1. Perry RT, Plowe CV, Koumaré B, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. 1998. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. Bull World Health Organ 76:63–71.
    1. Ratanasuwan W, Kim YH, Sah BK, Suwanagool S, Kim DR, Anekthananon A, Lopez AL, Techasathit W, Grahek SL, Clemens JD, Wierzba TF. 2015. Peru-15 (Choleragarde®), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand. Vaccine 33:4820–4826. doi:10.1016/j.vaccine.2015.07.073.
    1. Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB. 2011. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin Immunol 139:185–192. doi:10.1016/j.clim.2011.02.003.
    1. Wahid R, Simon JK, Picking WL, Kotloff KL, Levine MM, Sztein MB. 2013. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin Immunol 148:35–43. doi:10.1016/j.clim.2013.03.009.
    1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:209–222. doi:10.1016/S0140-6736(13)60844-2.
    1. Rennels MB, Levine MM, Daya V, Angle P, Young C. 1980. Selective vs. nonselective media and direct plating versus. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J Infect Dis 142:328–331. doi:10.1093/infdis/142.3.328.
    1. Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM, Craig JP. 1982. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis 145:465–473. doi:10.1093/infdis/145.4.465.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner